Flamel Technologies (NASDAQ:FLML) has had a string of rather good news. It recently received FDA approval for its drug Bloxiverz. What is even better is the fact that Flamel already has a rather substantial amount of income coming in for a small-cap stock. With all of this good news, there is still a large amount of upside potential left for this stock. The one main problem with Flamel Technologies is in the fact that it is hesitant to report key information about its drugs in development. This makes planning for the long term to be much more of a guessing game than usual (which is already a huge guessing game). However, this represents interesting catalysts depending on...
|FREE||SA PRO MEMBERS|
|IDEA GENERATOR||X||Exclusive access to 10 PRO ideas every day|
|INVESTING IDEAS LIBRARY||X||Exclusive access to PRO library of more than 15,000 ideas|
|SECTOR EXPERT NETWORK||X||Exclusive access to all sector experts for direct consultation|
|PERFORMANCE TRACKING||X||Track performance of all PRO stock ideas|
|PROFESSIONAL TOOLS||X||Professional Idea Filters to zero-in based on industry, market cap and more|